Immune checkpoint inhibitor-bullous pemphigoid is characterized by interleukin-4 and interleukin-13 expression and responds to dupilumab treatment.

Immune check point inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune related adverse event in need of novel therapeutic approaches, as conventional therapy treatment can counteract intended tumor immunity. Here we demonstrate that IL4 and IL13 cytokine expression is elevated in ICI-BP similar to conventional autoimmune bullous pemphigoid and further demonstrate partial and complete disease clearance in four ICI-BP patients with dupilumab. These data indicate that IL-4Ralpha inhibition may be a promising new therapy for ICI-BP.